Chronic Lymphocytic Leukemia
March 2022 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Chronic Lymphocytic Leukemia abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Chronic Lymphocytic Leukemia. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Chronic Lymphocytic Leukemia. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Chronic Lymphocytic Leukemia every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:The role of minimal residual disease in chronic lymphocytic leukemia.
Authors:Al-Sawaf O, Hallek M, Fischer K
Institution:University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine; German CLL Study Group, Center for Integrated Oncology Aachen-Bonn-Cologne-Dusseldorf, Aachen, Germany.
Journal:Clin Adv Hematol Oncol. 2022 Feb;20(2):97-103.

2:Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
Authors:Arellano-Llamas AA, Vela-Ojeda J, Hernandez-Caballero A
Institution:Department of Endocrinology, UMAE Hospital General Centro Medico La Raza, Instituto Mexicano del Seguro Social, Seris y Zaachila, La Raza, Azcapotzalco, 02900, Mexico City, Mexico. Department of Hematology, UMAE Hospital de Especialidades Centro Medico La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico. alvheca@gmail.com.
Journal:Curr Oncol Rep. 2022 Feb;24(2):209-213. doi: 10.1007/s11912-022-01198-z. Epub 2022 Jan 21.

3:Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
Authors:Cull G, Burger JA, Opat S, Gottlieb D, Verner E, Trotman J, Marlton P, Munoz J, Johnston P, Simpson D, Stern JC, Prathikanti R, Wu K, Novotny W, Huang J, Tam CS
Institution:Sir Charles Gairdner Hospital, Perth, WA, Australia. Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Journal:Br J Haematol. 2022 Mar;196(5):1209-1218. doi: 10.1111/bjh.17994. Epub 2021 Dec 16.

4:Frontline treatment in CLL: the case for time-limited treatment.
Authors:Lévy V, Delmer A, Cymbalista F
Institution:Departement de Recherche Clinique, Hopital Avicenne AP-HP, Universite Sorbonne Paris Nord, Bobigny, France, and INSERM CRESS-UMR 1153, Hopital Saint Louis, Paris, France. Hematology Biology, Hopital Avicenne, AP-HP, Universite Sorbonne Paris Nord, Bobigny, France, and INSERM UMR 978, Bobigny, France.
Journal:Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):59-67. doi: 10.1182/hematology.2021000233.

5:Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Authors:Allan JN, Shanafelt T, Wiestner A, Moreno C, O'Brien SM, Li J, Krigsfeld G, Dean JP, Ahn IE
Institution:Weill Cornell Medicine, New York, NY, USA. National Heart, Lung, and Blood Institute, Bethesda, MD, USA.
Journal:Br J Haematol. 2022 Feb;196(4):947-953. doi: 10.1111/bjh.17984. Epub 2021 Dec 5.

6:Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.
Authors:Soumerai JD, Mato AR, Dogan A, Seshan VE, Joffe E, Flaherty K, Carter J, Hochberg E, Barnes JA, Hamilton AM, Abramson JS, Batlevi CL, Matasar MJ, Noy A, Owens CN, Palomba ML, Kumar A, Takvorian T, Ni A, Choma M, Friedman C, Chadha P, Simkins E, Ruiters J, Sechio S, Portman D, Ramos L, Nolet N, Mahajan N, Martignetti R, Mi J, Scorsune K, Lynch J, McGree B, Hughes S, Grieve C, Roeker LE, Thompson M, Johnson PC, Roshal M, Huang J, Biondo J, Wu Q, Jacob A, Abdel-Wahab O, Zelenetz AD
Institution:Massachusetts General Hospital Cancer Center, Boston, MA, USA. Memorial-Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: zeleneta@mskcc.org.
Journal:Lancet Haematol. 2021 Dec;8(12):e879-e890. doi: 10.1016/S2352-3026(21)00307-0.

7:Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
Authors:Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, Montegaard J, Ihuoma U, Lehmberg TZ, Parry EM, Wu CJ, Jacobson CA, Fisher DC, Thompson PA, Brown JR
Institution:Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Journal:Blood. 2022 Feb 3;139(5):686-689. doi: 10.1182/blood.2021011386.

8:The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Authors:Langerbeins P, Zhang C, Robrecht S, Cramer P, Fürstenau M, Al-Sawaf O, von Tresckow J, Fink AM, Kreuzer KA, Vehling-Kaiser U, Tausch E, Müller L, Eckart MJ, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Wendtner CM, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M
Institution:Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Duesseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Journal:Blood. 2022 Jan 13;139(2):177-187. doi: 10.1182/blood.2021010845.

9:Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study.
Authors:Eyre TA, Schuh A, Wierda WG, Brown JR, Ghia P, Pagel JM, Furman RR, Cheung J, Hamdy A, Izumi R, Patel P, Wang MH, Xu Y, Byrd JC, Hillmen P
Institution:Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: toby.eyre@ouh.nhs.uk. St James's University Hospital, Leeds, UK.
Journal:Lancet Haematol. 2021 Dec;8(12):e912-e921. doi: 10.1016/S2352-3026(21)00305-7. Epub 2021 Nov 1.

10:COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.
Authors:Chatzikonstantinou T, Kapetanakis A, Scarfò L, Karakatsoulis G, Allsup D, Cabrero AA, Andres M, Antic D, Baile M, Baliakas P, Bron D, Capasso A, Chatzileontiadou S, Cordoba R, Correa JG, Cuéllar-García C, De Paoli L, De Paolis MR, Del Poeta G, Demosthenous C, Dimou M, Donaldson D, Doubek M, Efstathopoulou M, Eichhorst B, El-Ashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Frederiksen H, Fürstenau M, García-Marco JA, García-Serra R, Gentile M, Gimeno E, Glenthøj A, Gomes da Silva M, Gutwein O, Hakobyan YK, Herishanu Y, Hernández-Rivas JÁ, Herold T, Innocenti I, Itchaki G, Jaksic O, Janssens A, Kalashnikova ОB, Kalicińska E, Karlsson LK, Kater AP, Kersting S, Labrador J, Lad D, Laurenti L, Levin MD, Lista E, Lopez-Garcia A, Malerba L, Marasca R, Marchetti M, Marquet J, Mattsson M, Mauro FR, Milosevic I, Mirás F, Morawska M, Motta M, Munir T, Murru R, Niemann CU, Rodrigues RN, Olivieri J, Orsucci L, Papaioannou M, Pavlovsky MA, Piskunova I, Popov VM, Quaglia FM, Quaresmini G, Qvist K, Reda G, Rigolin GM, Ruchlemer R, Saghumyan G, Shrestha A, Šimkovič M, Špaček M, Sportoletti P, Stanca O, Stavroyianni N, Tadmor T, Te Raa D, Tonino SH, Trentin L, Van Der Spek E, van Gelder M, van Kampen R, Varettoni M, Visentin A, Vitale C, Wasik-Szczepanek E, Wróbel T, San Segundo LY, Yassin M, Coscia M, Rambaldi A, Montserrat E, Foà R, Cuneo A, Stamatopoulos K, Ghia P
Institution:Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece. Universita Vita-Salute San Raffaele and IRCC Ospedale San Raffaele, Milan, Italy. ghia.paolo@hsr.it.
Journal:Leukemia. 2021 Dec;35(12):3444-3454. doi: 10.1038/s41375-021-01450-8. Epub 2021 Nov 1.

11:Cardiovascular complications associated with novel agents in the chronic lymphocytic leukemia armamentarium: A pharmacovigilance analysis.
Authors:Grewal US, Thotamgari SR, Sheth AR, Gaddam SJ, Ahmad J, Beedupalli K, Dominic P
Institution:Department of Internal Medicine, Louisiana State University Health Sciences Center, Shreveport, LA, USA. Division of Cardiology, Department of Medicine, and Center for Cardiovascular Diseases and Sciences, Louisiana State University Health Sciences Center, Shreveport, LA, USA. Electronic address: paari.dominic@lsuhs.edu.
Journal:Int J Cardiol. 2021 Dec 1;344:186-189. doi: 10.1016/j.ijcard.2021.10.011. Epub 2021 Oct 12.

12:Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
Authors:Hallek M, Al-Sawaf O
Institution:Department I of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Center of Excellence on "Cellular Stress Responses in Aging-Associated Diseases", University of Cologne, Köln, Germany. Oncology Aachen Bonn Köln Düsseldorf, Center of Excellence on "Cellular Stress Responses in Aging-Associated Diseases", University of Cologne, Köln, Germany.
Journal:Am J Hematol. 2021 Dec 1;96(12):1679-1705. doi: 10.1002/ajh.26367.

13:Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
Authors:Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, Badoux XC, Kuss BJ, Jackson S, Moreno C, Jacobs R, Pagel JM, Flinn I, Pak Y, Zhou C, Szafer-Glusman E, Ninomoto J, Dean JP, James DF, Ghia P, Tam CS
Institution:Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX. Spain. Seattle, WA. Melbourne, Melbourne, VIC, Australia.
Journal:J Clin Oncol. 2021 Dec 1;39(34):3853-3865. doi: 10.1200/JCO.21.00807. Epub 2021 Oct 7.

14:Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.
Authors:Blixt L, Bogdanovic G, Buggert M, Gao Y, Hober S, Healy K, Johansson H, Kjellander C, Mravinacova S, Muschiol S, Nilsson P, Palma M, Pin E, Smith CIE, Stromberg O, Sällberg Chen M, Zain R, Hansson L, Österborg A
Institution:Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden.
Journal:Leukemia. 2022 Feb;36(2):476-481. doi: 10.1038/s41375-021-01424-w. Epub 2021 Sep 25.

15:Chronic lymphocytic leukemia in a young population.
Authors:Alshemmari SH, Hamdah A, Pandita R, Kunhikrishnan A
Institution:Department of Medicine, Faculty of Medicine, Kuwait; Department of Hematology, Kuwait Cancer Center, Kuwait. Electronic address: salem@hsc.edu.kw.
Journal:Leuk Res. 2021 Nov;110:106668. doi: 10.1016/j.leukres.2021.106668. Epub 2021 Jul 15.

16:The road to chemotherapy-free treatment in chronic lymphocytic leukaemia.
Authors:Albiol N, Arguello-Tomas M, Moreno C
Institution:Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
Journal:Curr Opin Oncol. 2021 Nov 1;33(6):670-680. doi: 10.1097/CCO.0000000000000791.

17:Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study.
Authors:Abdel-Qadir H, Sabrie N, Leong D, Pang A, Austin PC, Prica A, Nanthakumar K, Calvillo-Argüelles O, Lee DS, Thavendiranathan P
Institution:Division of Cardiology and Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada. Division of Cardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, University Health Network, Toronto, Ontario, Canada.
Journal:J Clin Oncol. 2021 Nov 1;39(31):3453-3462. doi: 10.1200/JCO.21.00693. Epub 2021 Aug 31.

18:Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
Authors:Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O'Brien S, Yenerel MN, Illés A, Kay N, Garcia-Marco JA, Mato A, Pinilla-Ibarz J, Seymour JF, Lepretre S, Stilgenbauer S, Robak T, Rothbaum W, Izumi R, Hamdy A, Patel P, Higgins K, Sohoni S, Jurczak W
Institution:The Ohio State University Comprehensive Cancer Center, Columbus, OH. Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland.
Journal:J Clin Oncol. 2021 Nov 1;39(31):3441-3452. doi: 10.1200/JCO.21.01210. Epub 2021 Jul 26.

19:Frequency, variations, and prognostic implications of chromosome 14q32 deletions in chronic lymphocytic leukemia.
Authors:Harris RA, Stevens JM, Pickering DL, Althof PA, Smith LM, Sanmann JN, Dave BJ
Institution:Human Genetics Laboratory, University of Nebraska Medical Center, Omaha, NE, United States. States. States. States. United States. States. States. Electronic address: bdave@unmc.edu.
Journal:Leuk Res. 2021 Nov;110:106665. doi: 10.1016/j.leukres.2021.106665. Epub 2021 Jul 11.

20:Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves.
Authors:Alrawashdh N, Persky DO, McBride A, Sweasy J, Erstad B, Abraham I
Institution:Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ; Department of Clinical Translational Sciences, College of Medicine, University of Arizona, Tucson, AZ. Tucson, AZ. Tucson, AZ; Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ. Tucson, AZ; University of Arizona Cancer Center, Tucson, AZ; Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ. Electronic address: abraham@pharmacy.arizona.edu.
Journal:Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):e820-e831. doi: 10.1016/j.clml.2021.06.010. Epub 2021 Jun 23.

21:Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.
Authors:Wierda WG, Rawstron A, Cymbalista F, Badoux X, Rossi D, Brown JR, Egle A, Abello V, Cervera Ceballos E, Herishanu Y, Mulligan SP, Niemann CU, Diong CP, Soysal T, Suzuki R, Tran HTT, Wu SJ, Owen C, Stilgenbauer S, Ghia P, Hillmen P
Institution:MD Anderson Cancer Center, Houston, TX, USA. wwierda@mdanderson.org. Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Cancer Cluster Salzburg, Salzburg, Austria. Mexico. University, Homburg, Germany.
Journal:Leukemia. 2021 Nov;35(11):3059-3072. doi: 10.1038/s41375-021-01241-1. Epub 2021 Jun 24.

22:Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Authors:Cramer P, Tausch E, von Tresckow J, Giza A, Robrecht S, Schneider C, Fürstenau M, Langerbeins P, Al-Sawaf O, Pelzer BW, Fink AM, Fischer K, Wendtner CM, Eichhorst B, Kneba M, Stilgenbauer S, Hallek M
Institution:Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. Cologne Duesseldorf (CIO ABCD) and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. University Hospital Essen, University of Duisburg-Essen, Essen, Germany. Cologne Duesseldorf (CIO ABCD) and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. Cologne Duesseldorf (CIO ABCD) and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. Cologne Duesseldorf (CIO ABCD) and German CLL Study Group, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Journal:Blood. 2021 Nov 11;138(19):1805-1816. doi: 10.1182/blood.2020010484.

23:The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study.
Authors:Mato AR, Sharman JP, Biondo JML, Wu M, Mun Y, Kim SY, Humphrey K, Boyer M, Zhu Q, Seymour JF
Institution:Memorial Sloan Kettering Cancer Center, New York, NY. matoa@mskcc.org. Peter MacCallum Cancer Centre, Royal Melbourne Hospital, The University of Melbourne, Melbourne, VIC.
Journal:Haematologica. 2022 Jan 1;107(1):134-142. doi: 10.3324/haematol.2020.266486.

For a FREE PREVIEW of the Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Chronic Lymphocytic Leukemia...
at a Special 20% Discount


Medifocus Guidebook on Chronic Lymphocytic Leukemia

Updated: January 2, 2022
183 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Chronic Lymphocytic Leukemia is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $49.95
  • Less 20% Discount = - $10.00
  • Discounted Price = $39.95(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $34.95
  • Less 20% Discount = - $7.00
  • Discounted Price = $27.95

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

CL240402273

Coupon Expires: September 13, 2022



What Our Customers Are Saying...

"I was recently diagnosed with CLL and searched all over the Web for information. I found the MediFocus Guidebook on Chronic Lymphocytic Leukemia to be a very useful resource. The information about chemotherapy was most important to me as well as recent studies concerning general treatments for this condition. The most valuable information was contained in the extensive references listed which were easy to access with a simple 'mouse' click. You are welcome to use my name as a reference."
G.C.
Coedpoeth, United Kingdom



  
Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2022 Medifocus, Inc. All rights reserved.